---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-150187"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2022-05-13T23:59:59+00:00"
generated_at: "2026-06-25T16:39:23.400354+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Coherus appoints Jill O'Donnell-Tormey, Ph.D. to board effective May 18, 2022

## Summary
- Board expanded from 7 to 8 directors; O'Donnell-Tormey appointed as Class II director, term through 2025 annual meeting.
- She is CEO of Cancer Research Institute since 1993; also serves on boards of CUNY, Richmond University Medical Center.
- Will receive $50,000 annual cash retainer and option for 54,000 shares vesting over three years.
- Appointed to the Nominating Committee of the Board.

## SEC filing metadata
- accession: 0001193125-22-150187
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2022-05-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000119312522150187/0001193125-22-150187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000119312522150187/d287872d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-150187
- JSON: https://secwatch.observer/filing/0001193125-22-150187.json
- Plain text: https://secwatch.observer/filing/0001193125-22-150187.txt

## Key facts
- Executive change
  Jill O'Donnell-Tormey was appointed as Director at Coherus Oncology, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) increased the authorized number of directors that can serve on the Board from seven to eight directors and, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), resolved that the vacancy on the Board created by such increase would be filled with the appointment of Jill O’Donnell-Tormey, Ph.D. effective May 18, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000119312522150187/0001193125-22-150187-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.